Diabetes Research and Clinical Practice - Volume 120 - Supplement 1 - October 2016

120 / 244

treated with insulin glargine after failure of non-insulin
therapy, including the reasons for stopping insulin titration.
Material and methods: We performed an open label, non-
randomized, cross-sectional, non-interventional registry
study on 4601 adult T2DM patients (46.9% Males/53.1%
Females) treated for 5 –8 months with insulin glargine after
failure of non-insulin treatments. Study involved 220 study
sites in Romania. Mean age of patients was 61.25 years while
mean duration of diabetes was 7.63 years. A total of 84.1% of
patients were overweight or obese, with a mean BMI of
30.12 kg/m 2. Comparison between quantitative variables was
madewith the Student t test or Fisher exact test using the SPSS
v21 software.
Results: Mean HbA1c at initiation of insulin glargine (baseline)
was 9.4% while mean fasting plasma glucose (FBG) was
232.16 mg%. At that point 97.6% of patients received oral
antidiabetics (OADs), of which 74.6% SUs. Mean dose of insulin
glargine at treatment initiation was 16.4 IU (0.25 U/kg/day).
The majority of physicians planned to use the LANMET
titration protocol (in 72.3% of cases) and targeted a HbA1c
between 6.5% and 7% (in 66% of cases). Mean value of
HbA1c reported at the final visit was 7.3%, with an absolute
HbA1c reduction of 2.1%. FBG decreased to 128.61 mg/dL. At
final visit, the mean dosage of insulin glargine was 31.09 IU.
The most frequent reasons to stop insulin titration were
achieving target HbA1c (1904 patients – 41.4%) and FBG (2863
patients – 62.2%). Only 29 (0.63%) patients had documented
symptomatic hypoglycemia (BG < 70 mg/dL).
Conclusions: We found a significant decrease of HbA1c and
FBG on a cohort of Romanian T2DM patients treated for 5 –8
months with insulin glargine after failure of non-insulin
therapy. 41.4% of patients initiated on basal insulin glargine
could reach the HbA1c target and 62,2% of patients reached the
FPG target in the first 5 –8 months with an appropriate titration
according with the guidelines recommendations. Overall the
risk of hypoglycemia was low.
PD-33
Ipragliflozin, a novel SGLT2 inhibitor, improves blood glucose,
as shown by continuous glucose monitoring, and ameliorates
metabolic syndrome
Shojima SONEI1*. 1Okayama Saiseikai Hospital, Japan
Background and aims: Ipragliflozin (Suglat® ) was the first
selective SGLT2 inhibitor in Japan and has becomewidely used
since April 2014.
Our aims: To assess the plasma glucose changing and efficacy
and safety of Ipragliflozin.
Methods: T2DM patients with poor blood glucose control
received 50 mg Ipragliflozin once daily as monotherapy or as
additional therapy. Efficacy and safety were evaluated for 24
weeks. CGM was performed for one-week periods at week 0
and week 4.
Results: 14 patients were enrolled (male/female: 8/6; age:
53.6 ± 3.0 y; body weight: 79.6 ± 3.8 kg; BMI: 29.8 ± 1.0; HbA1c:
8.0 ± 0.4).
CGM: The daily blood glucose curve at week 4 was consistently
lower than baseline. The average whole-day blood glucosewas
decreased significantly, and nocturnal blood glucose, FPG, PPG,
postprandial AUC 0 –3h also tended to decrease. However,
indicators of fluctuation, such as MAGE and standard devi-
ation, were not changed significantly.
PD: The 24-h urinary glucose excretion and urinary volume
were significantly increased consistently around 90 g/day and
900 mL/day respectively.
Efficacy: The change in HbA1c was −0.8% (P < 0.01) from week
4 and continued until week 24. The change in body weight
was −2 to − 3 kg from week 4 (P < 0.01). Waist circumference,
blood pressure, HDL, and urinary urea were significantly
improved.
Safety: No serious adverse events (AEs), symptomatic hypo-
glycemia or dehydration occurred during the study. Mild AEs
based on PD, such as pollakiuria, polyuria, and hunger,
occurred more frequently in most patients.
Conclusion: Daily administration of Ipragliflozin was effective
in improving glycemic control, body weight, and metabolic
syndrome in Japanese obese T2DM patients with good safty
and tolerability. We conclude that Ipragliflozin can be bene-
ficial as monotherapy or in combination with other anti-
hyperglycemic regimens in the treatment of T2DM patients.
PD-35
The application of mobile APP for diabetic self-management in
adolescent with Type 1 diabetes
Ting Ju CAHN1*, Li-Chi HUANG2, Ching-Chu CHEN1,
Chung-Hsing WANG1, Kuei-Mei YEH1. 1China Medical University
Hospital, 2China Medical University, Adjunct Supervisor, CMU
Hospital, Taiwan
Purpose: Adolescence is an important stage in person’s
independence. Health educator must notice on adolescent
patients for learning independent decision-making and self-
care. The goal of this study is to assist a teenager with Type 1
diabetes by using mobile phone APP for blood glucose
management.
Methods: This study was conducted in a medical center in
central Taiwan fromAug. 7th to Sep. 23rd, 2015. Amobile blood
glucose self-management APP was used for assisting patient
self-care at home. The APP functions include: using instance
messages or reminder to assist the user in monitoring and
recording their blood glucose, diet, medication, and exercise
regime. The APP response was also provided including
synchronized and non-synchronized feedback. The effective-
ness of APP was evaluated by self-report diabetes manage-
ment scale, glycated hemoglobin (A1C), and average of blood
glucose levels.
Results: A 14 year-old participant was recruited with pre-
intervention, the average of blood glucose level was 147 mg/dL
(range: 54–341 mg/dL), and 72 times of abnormal blood glucose
measurements (out of 129 measurements). The average of
blood glucose was changed to 112 mg/dL (range: 63–181 mg/
dL), and 31 times of abnormal blood glucose measurements
(out of 120 measurements) after intervention. Also, the A1C
level was improved from 14% to 8.1% in this program. By APP
assistance, the patient’s satisfaction of diabetes self-manage-
ment was high as 90%. The APP can be used to record patient’s
daily diet and provide suggestions for carbohydrate replace-
ment. Furthermore, with synchronized feedback in APP,
patient had a better and instant discussion with health
educators for blood glucose management.
Application: The use of mobile APP can provide promptly
consultation and visualization of blood glucose fluctuation.
The promptly education is one of valuable strategy in assisting
the adolescent patient in performing diabetes self-care,
learning self-management, and maintaining stable blood
glucose. Therefore, we suggest that the application of mobile
APP can be as good strategy in clinical health education.
PD-36
Clinical course after discontinuation of the SGLT2 inhibitor
tofogliflozin
Yukio IKEDA1*, Naoko HISAKAWA1. 1Diabetes Center, Kochi
Memorial Hospital, Japan
Objectives: Sodium-glucose co-transporter 2 (SGLT2) inhibi-
tors induce glycosuria, reduce glucose toxicity and improve
insulin sensitivity and β-cell function. In addition, they have
other potential benefits in terms of weight loss and reduction
of blood pressure. However, in contrast, increased risk of
genital and urinary tract infections and osmotic diuresis-
related adverse events are consistently reported with the use
Poster Presentations / Diabetes Research and Clinical Practice 120S1 (2016) S65–S211 S102